US20130041013A1 - Isoform of bruton's tyrosine kinase (btk) protein - Google Patents
Isoform of bruton's tyrosine kinase (btk) protein Download PDFInfo
- Publication number
- US20130041013A1 US20130041013A1 US13/532,677 US201213532677A US2013041013A1 US 20130041013 A1 US20130041013 A1 US 20130041013A1 US 201213532677 A US201213532677 A US 201213532677A US 2013041013 A1 US2013041013 A1 US 2013041013A1
- Authority
- US
- United States
- Prior art keywords
- gene
- tumour
- cells
- gsk3
- btk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 84
- 102000001708 Protein Isoforms Human genes 0.000 title claims description 21
- 108010029485 Protein Isoforms Proteins 0.000 title claims description 21
- 102000004169 proteins and genes Human genes 0.000 title claims description 19
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 33
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract description 32
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 21
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 230000000903 blocking effect Effects 0.000 claims abstract description 16
- 101150113453 Gsk3a gene Proteins 0.000 claims abstract description 14
- 210000000130 stem cell Anatomy 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 48
- 229960002949 fluorouracil Drugs 0.000 claims description 48
- 108020004999 messenger RNA Proteins 0.000 claims description 33
- 230000030833 cell death Effects 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 22
- 108020004459 Small interfering RNA Proteins 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 108060006662 GSK3 Proteins 0.000 claims description 14
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 14
- 239000004055 small Interfering RNA Substances 0.000 claims description 14
- 102000001267 GSK3 Human genes 0.000 claims description 12
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims description 12
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 12
- 229960001756 oxaliplatin Drugs 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000012623 DNA damaging agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 101100176783 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) GSK3 gene Proteins 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000009007 Diagnostic Kit Methods 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- PMJIHLSCWIDGMD-UHFFFAOYSA-N tideglusib Chemical compound O=C1SN(C=2C3=CC=CC=C3C=CC=2)C(=O)N1CC1=CC=CC=C1 PMJIHLSCWIDGMD-UHFFFAOYSA-N 0.000 claims 1
- 229950005284 tideglusib Drugs 0.000 claims 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 abstract description 82
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 abstract description 75
- 206010059866 Drug resistance Diseases 0.000 abstract description 17
- 108010055196 EphA2 Receptor Proteins 0.000 abstract description 6
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 abstract description 6
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 abstract description 6
- 101000938354 Homo sapiens Ephrin type-A receptor 1 Proteins 0.000 abstract description 6
- 108010055155 EphA8 Receptor Proteins 0.000 abstract description 5
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 abstract description 5
- 101000977768 Homo sapiens Interleukin-1 receptor-associated kinase 3 Proteins 0.000 abstract description 5
- 101001042360 Homo sapiens LIM domain kinase 2 Proteins 0.000 abstract description 5
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 abstract description 5
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract description 5
- 101000721642 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Proteins 0.000 abstract description 5
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 abstract description 5
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 abstract description 5
- 102100023530 Interleukin-1 receptor-associated kinase 3 Human genes 0.000 abstract description 5
- 102100021756 LIM domain kinase 2 Human genes 0.000 abstract description 5
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract description 5
- 102100025058 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Human genes 0.000 abstract description 5
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 abstract description 5
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 abstract description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract description 5
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 abstract description 4
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 abstract description 4
- 108010055334 EphB2 Receptor Proteins 0.000 abstract description 4
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 abstract description 4
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 abstract description 4
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 abstract description 4
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 abstract description 4
- 101000974343 Homo sapiens Nuclear receptor coactivator 4 Proteins 0.000 abstract description 4
- 101000801664 Homo sapiens Nucleoprotein TPR Proteins 0.000 abstract description 4
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 abstract description 4
- 101000584593 Homo sapiens Receptor activity-modifying protein 3 Proteins 0.000 abstract description 4
- 101001047642 Homo sapiens Serine/threonine-protein kinase LATS1 Proteins 0.000 abstract description 4
- 101000714920 Homo sapiens Taste receptor type 2 member 13 Proteins 0.000 abstract description 4
- 101000766345 Homo sapiens Tribbles homolog 3 Proteins 0.000 abstract description 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 abstract description 4
- 102100022927 Nuclear receptor coactivator 4 Human genes 0.000 abstract description 4
- 102100033615 Nucleoprotein TPR Human genes 0.000 abstract description 4
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 abstract description 4
- 102100030711 Receptor activity-modifying protein 3 Human genes 0.000 abstract description 4
- 102100024031 Serine/threonine-protein kinase LATS1 Human genes 0.000 abstract description 4
- 102100026390 Tribbles homolog 3 Human genes 0.000 abstract description 4
- 230000007170 pathology Effects 0.000 abstract description 4
- 102100033409 40S ribosomal protein S3 Human genes 0.000 abstract description 3
- 101000656561 Homo sapiens 40S ribosomal protein S3 Proteins 0.000 abstract description 3
- 101001052477 Homo sapiens Mitogen-activated protein kinase 4 Proteins 0.000 abstract description 3
- 101001002122 Homo sapiens Phospholemman Proteins 0.000 abstract description 3
- 101000738945 Homo sapiens Proline-rich nuclear receptor coactivator 2 Proteins 0.000 abstract description 3
- 101000933601 Homo sapiens Protein BTG1 Proteins 0.000 abstract description 3
- 101000584590 Homo sapiens Receptor activity-modifying protein 2 Proteins 0.000 abstract description 3
- 101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 abstract description 3
- 102100024189 Mitogen-activated protein kinase 4 Human genes 0.000 abstract description 3
- 102100028470 Nuclear receptor subfamily 2 group C member 1 Human genes 0.000 abstract description 3
- 102100035969 Phospholemman Human genes 0.000 abstract description 3
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 abstract description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 abstract description 3
- 102100037393 Proline-rich nuclear receptor coactivator 2 Human genes 0.000 abstract description 3
- 102100026036 Protein BTG1 Human genes 0.000 abstract description 3
- 102100030696 Receptor activity-modifying protein 2 Human genes 0.000 abstract description 3
- 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 abstract description 3
- 102000003564 TRPC7 Human genes 0.000 abstract description 3
- 101150095096 TRPM2 gene Proteins 0.000 abstract description 3
- 101150033973 Trpc7 gene Proteins 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 108091008744 testicular receptors 2 Proteins 0.000 abstract description 3
- 102100036850 C-C motif chemokine 23 Human genes 0.000 abstract description 2
- 102100031060 Clarin-1 Human genes 0.000 abstract description 2
- 102100039524 DNA endonuclease RBBP8 Human genes 0.000 abstract description 2
- -1 ERNI Proteins 0.000 abstract description 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 abstract description 2
- 101000992973 Homo sapiens Clarin-1 Proteins 0.000 abstract description 2
- 101000746134 Homo sapiens DNA endonuclease RBBP8 Proteins 0.000 abstract description 2
- 101001022780 Homo sapiens Myosin light chain kinase, smooth muscle Proteins 0.000 abstract description 2
- 101000794213 Homo sapiens Thymus-specific serine protease Proteins 0.000 abstract description 2
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 abstract description 2
- 101700056750 PAK1 Proteins 0.000 abstract description 2
- 102100027910 Serine/threonine-protein kinase PAK 1 Human genes 0.000 abstract description 2
- 102100030138 Thymus-specific serine protease Human genes 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 110
- 230000030279 gene silencing Effects 0.000 description 25
- 239000013598 vector Substances 0.000 description 20
- 210000001072 colon Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 206010057248 Cell death Diseases 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 230000001177 retroviral effect Effects 0.000 description 8
- 230000009368 gene silencing by RNA Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 5
- UVSVTDVJQAJIFG-VURMDHGXSA-N LFM-A13 Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC(Br)=CC=C1Br UVSVTDVJQAJIFG-VURMDHGXSA-N 0.000 description 5
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229950010131 puromycin Drugs 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000001173 tumoral effect Effects 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- 102000018832 Cytochromes Human genes 0.000 description 4
- 108010052832 Cytochromes Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 208000037828 epithelial carcinoma Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 101150030812 BTK gene Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 2
- 102000047934 Caspase-3/7 Human genes 0.000 description 2
- 108700037887 Caspase-3/7 Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 102100030013 Endoribonuclease Human genes 0.000 description 2
- 108091006081 Inositol-requiring enzyme-1 Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000006743 cytoplasmic accumulation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 102100031002 60S ribosomal protein L36a Human genes 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101001127203 Homo sapiens 60S ribosomal protein L36a Proteins 0.000 description 1
- 101001127258 Homo sapiens 60S ribosomal protein L36a-like Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PHSUOGLOGCYOJU-UXBLZVDNSA-N [C-]#[N+]/C(C(=O)NC1=CC(Br)=CC=C1Br)=C(\C)O Chemical compound [C-]#[N+]/C(C(=O)NC1=CC(Br)=CC=C1Br)=C(\C)O PHSUOGLOGCYOJU-UXBLZVDNSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000011328 necessary treatment Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention regards the use of compounds for the production of a medicament capable of modulating, and in particular diminishing the drug resistance in human epithelial tumour cells, according to the characteristics stated in the preamble of the main claim. It is also intended for a determination method of the drug resistance in tumour cells as well as a method for the identification of tumour stem cells.
- tumour cells may respond in an unexpected manner to the drug therapy, showing, on the contrary, a strong resistance to the same. It is also known that one of the main reasons for the drug resistance shown by the tumour cells is the incapacity of the cells to begin the process of apoptosis, even in the presence of considerable DNA damage.
- tumour cells of the colon-rectum in advanced phase a drug therapy based on 5-fluorouracil (5FU) shows an effective response only for 10-15% of the cells, and a combination of 5FU with new drugs such as irinotecan and oxaliplatin leads to an increase of the cell mortality up to 40-50%, a value which is still entirely unsatisfactory for an effective therapeutic action towards the neoplastic pathologies.
- 5FU 5-fluorouracil
- RNA interference RNA interference
- the problem underlying the present invention is that of making available compounds capable of reducing the drug resistance of the tumour cells of epithelial type, in order to permit the manufacture of medicaments destined for the therapy of related neoplastic pathologies.
- this invention moreover provides a method for the determination of the drug resistance of epithelial tumour cell lines.
- this invention moreover provides a method for the identification of tumour stem cells.
- FIG. 1 is a graph illustrating the results of inhibition of the capacity to form drug-resistant tumour cell colonies of the colon treated with the compounds according to the invention and a chemotherapeutic drug
- FIGS. 2 a and 2 b are graphs showing the results of an analysis of reversion of the resistance of a tumour cell line to two different chemotherapeutic drugs by means of silencing of the alpha and beta isoforms of the gene GSK3,
- FIGS. 3 a - 3 c are graphs illustrating the results of the tests of reversion of the resistance to a chemotherapeutic drug of three different tumour cell lines of the colon by means of silencing of the gene GSK3beta,
- FIG. 4 a is a graph illustrating the results of the tests of reversion of the resistance to a different chemotherapeutic drug of two different tumour cell lines of the colon by means of silencing of the gene GSK3beta,
- FIG. 4 b is a graph illustrating the results of an analysis of reversion of the resistance of a tumour cell line to the combination of two different chemotherapeutic drugs by means of the silencing of the beta isoform of the gene GSK3,
- FIG. 5 is a collection of images illustrating the location of cytochrome C for 5FU-induced cell death in the absence of GSK3.
- FIG. 6 is a graph illustrating the results of caspase 3 and caspase 7 activation assays in response to 5FU treatment of HCT116 and GSK3alpha, GSK3beta gene silenced HCT116p53KO colon carcinoma cells,
- FIG. 7 is a collection of images illustrating the translocation of AIF to the nucleus during 5FU-induced cell death in the absence of GSK3,
- FIG. 8 is a graph illustrating the reversion of the resistance to a chemotherapeutic drug of a tumour cell line carried out by means of functional blocking of the gene BTK obtained with different methods
- FIG. 9 is a graph illustrating the percentage of cell death induced by 5FU upon BTK overexpression in HCT116 colon carcinoma cells
- FIGS. 10 a and 10 b are graphs illustrating the reversion of the resistance to chemotherapeutic drugs by means of the functional blocking of the gene BTK on different colon tumour cell lines,
- FIG. 11 is a western blot analysis showing BTK expression in several tumoral cell lines derived from different epithelial cancers
- FIGS. 12 a and 12 b are graphs illustrating the reversion of the resistance to chemotherapeutic drugs by means of the functional blocking of the gene BTK on epithelial tumour cell lines other than colon,
- FIG. 13 is collection of images illustrating the cytoplasmic accumulation of cytochrome C in 5FU-treated cells upon BTK inhibition
- FIG. 14 is a graph illustrating the results of fluorimetric caspase activation assays after 72 hrs and 96 hrs in HCT116 and HCT116p53KO colon carcinoma cells treated with 5FU, BTK inhibition, or the combination of the two,
- FIG. 15 a is western blot image showing that antibody sc-1696 specifically recognizes BTK protein and that in epithelial carcinoma cells (HCT116p53KO) BTK has an apparent molecular weight of ⁇ 67 kDa and that the same form of the protein is present, together with the “classic” 77 kDa form, also in leukemic cells (Nalm6),
- FIG. 15 b is an immunoprecipitation-western blot image confirming that also a different antibody (BL7) identify BTK protein as being ⁇ 67 kDa in HCT116p53KO cells and that this isoform is present in leukemic cells (Nalm6) together with the “classic” 77 kDa form,
- FIG. 16 is an image illustrating the results of a PCR experiment showing that the 5′ end upstream of nucleotide 202 in the BTK-encoding mRNA from HCT116p53KO cells is absent or different from the 5′ end of BTK mRNA from peripheral blood mononuclear cells (PBMC),
- PBMC peripheral blood mononuclear cells
- FIG. 17 is an image illustrating the results of ClustalW alignment of BTK transcript, identified by GenBank Accession #NM — 000061, and the novel transcript identified in HCT116p53KO cells by 5′RACE PCR followed by cloning and sequencing (indicated as alternative), the box outlining the part of BTK sequence (starting from nucleotide 131 of the known transcript) common between BTK mRNA deriving from #NM — 000061 and the novel BTK transcript found in HCT116p53KO,
- FIG. 18 is an image illustrating the results of a Blast alignment vs a genomic database of exons 1-5 of BTK transcript identified by GenBank Accession # NM — 000061 and the same exons of the novel BTK transcript, the dots indicating the position on chromosome X of the different exons of BTK,
- FIG. 19 is an image illustrating the results of a nested PCR experiment showing that the novel BTK transcript is expressed in Formalin-Fixed Paraffin-Embedded (FFPE) tumoral tissues from coloncarcinoma patients.
- FFPE Formalin-Fixed Paraffin-Embedded
- Such identification was conducted by means of phenotypic screening of a representative cell line of the epithelial tumour cells following the selective silencing of an extended group of genes by means of RNAi.
- siRNA a specific oligonucleotide molecule in a stable manner, known as small interference RNA, in brief siRNA, capable of blocking the translation process of a specific messenger RNA (mRNA) in the corresponding protein.
- siRNA messenger RNA
- Such mechanism in brief, foresees that the siRNA molecule (or rather a filament thereof) is associated with the RISC enzymatic complex, activating it, such that the latter can recognise and bind to the mRNA complementary to the siRNA associated thereto and then degrade it.
- siRNA mRNA, identified in a specific manner by the siRNA, cannot be translated in the corresponding amino acid chain, thus obtaining the silencing of the gene from which the mRNA was transcribed.
- the interference process is specific, so that a siRNA molecule is normally capable of degrading only one mRNA and therefore silencing one single gene.
- siRNA it is instead possible that the same mRNA can be degraded, via RISC, by different siRNA.
- shRNAs short hairpin RNAs
- a vector is used to introduce and incorporate shRNA into the cell chromosome. Transcription of the DNA produces shRNA which is subsequently cleaved by the cellular machinery, DICER, into siRNA. The siRNA then functions as previously mentioned.
- the incorporation of the shRNA vector into the cell chromosome allows for the gene silencing to be inherited by daughter cells. Thus the usage of shRNAs allows for functional knock out cells that can be used for long term experiments.
- the retroviral library arranged by the Bernards laboratories consists of about 25,000 different elements, capable of silencing about 8,300 genes of the human genome, with a ratio of about 3 different vectors for each gene.
- the tests were initially conducted in vitro and subsequently validated ex vivo on different epithelial tumour cell lines, characterised by the lack of or by the mutation of the gene p53 and hence provided with a marked resistance to chemotherapeutic drugs.
- a human RNAi library (NKi library) was established, consisting of 8,300 targeted genes for silencing.
- the targeted genes included kinases, phosphatases, oncogenes, tumor suppressors, transcription factors, genes involved in transformation, metastasis, cell cycle, differentiation, apoptosis, metabolic and anabolic processes.
- a protocol was followed similar to that mentioned in a prior publication (Berns et al., NATURE vol. 428, 25 March 2004). The contents of this publication are incorporated by reference into this application.
- the mRNA sequence for each targeted gene was selected from UniGene. The sequences were masked using RepeatMasker to remove repetitive sequences and searched with NCBI BLAST against UniVec to mask for vector contamination.
- RNA sequences for silencing each targeted gene were designed, for a total of approximately 25,000 59-mer oligonucleotides that specify short hairpin RNAs (shRNAs).
- the 19-mer sequences were selected using a selection criteria as mentioned in the Berns publication wherein, a) there were no stretches of four or more consecutive T or A residues (to avoid premature polymerase III transcription termination signals); b) to have 30-70% overall GC content; c) to lie within the coding sequence of the target gene; d) to begin with a G or C residue (consistent with recently established rules for strand bias); e) to begin after an AA dimer in the 5′ flanking sequence; f) to end just prior to a TT, TG or GT doublet in the 3′ flanking sequence; g) to not contain XhoI or EcoRI restriction enzyme sites to facilitate subsequent shuttling of the knockdown cassette into vector backbones; h) to share minimal sequence identity with other genes
- the 59-mer oligonucleotides were designed as to contain a 19-mer sequence, its complimentary 19-mer sequence, pol_III transcription initiation site, pol_III termination site, and HindIII/BglII cloning sites. Utilizing the HindIII/BglII cloning sites, the oligonucleotides were ligated into pRetroSuper (pRS) retroviral vectors, which included a selection cassette for puromycin resistance. The DNA from the three different vectors that targeted the same gene was pooled and virus was produced to infect target cells.
- pRS pRetroSuper
- tumour cell line initially used was HCT116p53KO (which differs from the wild type wt HCT116 due to the lack of gene p53), related to the colon tumour, while further detailed studies of specific genes were carried out on other drug-resistant tumour cell lines of the colon, such as DLD-1 and SW480, as well as on other tumour cell lines of the lung and ovary.
- all cell lines, object of the analysis were related to tumours of epithelial type.
- cell lines HCT116p53KO, DLD-1 and SW480 were treated with common chemotherapeutic drugs in order to confirm their resistance to the drug-induced apoptosis.
- chemotherapeutic drugs usable in accordance with the present invention can be of any type suitable for inducing the apoptosis process in the affected tumour cells, such as for example an antimetabolite or any DNA-damaging agent comprising the inhibitors of the topoisomerase I, inhibitors of the topoisomerase II, the platinum coordination compounds and alkylating agents.
- the aforesaid preliminary tests have shown how, after treatment for 72 hours in 200 ⁇ M 5FU, the cell mortality was less than 10%, against a wt HCR116 cell mortality of greater than 95%.
- the still-living cells were then collected, which therefore comprised all of the cells infected by the retroviruses of the library whose silenced genes were not incompatible with the cellular survival.
- the cells thus collected were then treated with 200 ⁇ M 5FU for 72 hours, while at the same time wt HCT116 cells and uninfected HCT116p53KO cells were also subjected to the same treatment, as controls.
- such treatments comprised of the extraction of the DNA and the amplification by means of PCR (Polymerase Chain Reaction) of a region of 643 base pairs containing the region H1 of a specific promoter and the adjacent region coding the nucleotide sequence of interest.
- PCR amplification was performed using a pRS-fw primer: 5′-CCCTTGAACCTCCTCGTTCGACC-3′ and pRS-rev primer: 5′-GAGACGTGCTACTTCCATTTGTC-3′.
- the products obtained by the amplification were then bound in pRS retroviral vectors and the infection process of HCT115p53KO cells was completely repeated with the new vectors, so as to refine the screening.
- the products were digested with EcoRI/XhoI and recloned into pRS.
- the products obtained from the second amplification treatment with PCR on the DNA harvested from the dead cells after new treatment with 5FU were newly isolated and bound in retroviral vectors pRS and then used for transforming DH5alpha bacteria whose respective plasmids were sequenced for the identification of the genes which gave rise to the phenotypic expression of interest.
- the validation was carried out in vitro on HCT116p53KO tumour cell samples, each of which separately infected with one of the previously-made plasmids, so as to silence in a specific and stable manner one of the genes indicated by the preceding screening and verify its capacity to modulate the resistance to drugs.
- the samples were then selected with puromycin, placed in Petri dishes at 50% confluence and treated with 200 ⁇ M of 5FU for 12 hours.
- the evaluation of the reversion of the drug resistance was carried out by means of observation of the formation of colonies according to the protocol defined by the CFA and their comparison with a wt HCT116 sample and an uninfected HCT116p53KO sample.
- FIG. 1 the results are reported in graph form which were obtained from this first in vitro validation. As clearly shown by the graph, a high percentage of identified genes are capable, when functionally blocked, of consistently reverting the colony forming ability of 5FU-treated HCT116p53KO cells. HCT116 and KO represent positive and negative controls.
- This first validation has in particular permitted identifying a group of genes whose specific silencing has given rise to a 5FU-induced inhibition of the growth of the tumour colonies greater than 50% with respect to the HCT116p53KO sample.
- a first subgroup is also identifiable of genes whose silencing advantageously leads to an over 75% inhibition of the tumour cells growth.
- Such first subgroup is formed by the following genes:
- a second subgroup was further identified of genes whose silencing advantageously leads to an over 95% inhibition of the growth of the tumour cells.
- EphA1 (2041), EphA2 (1969), EphA8 (2046), RAMP3 (10268), PIK3C2A (5286), GSK3beta (2932), IRAK3 (11213), DAPK1 (1612), CHEK1 (1111), PIM1 (5292), BTK (695), NCOA4 (8031), TPR (7185).
- FIG. 2 a compares the percentages of cell deaths in the absence (symbol “-”) and presence (symbol “+”) of 200 ⁇ M 5FU (72 hr treatment) upon wild type (wt) HCT116 cells, HCT116p53KO drug resistant cells, GSK3alpha and GSK3beta silenced gene cells.
- FIG. 2 b compares the percentages of cell deaths in the absence (symbol “ ⁇ ”) and presence (symbol “+”) of 50 ⁇ M oxaliplatin (72 hr treatment) upon wt HCT116 cells, HCT116p53KO drug resistant cells, GSK3alpha and GSK3beta silenced gene cells.
- HCT116p53KO cells with GSK3alpha and GSK3beta genes silenced also resulted in a high percentage of tumour cell death in the presence of oxaliplatin.
- the formal confirmation of the silencing of the specific genes by means of interference was carried out through Western Blot analysis of the levels of the protein coded by them, if the antibody was commercially available (EphA1, EphA2, CSF1R, VEGFR, GSK3, JAK1, CHEK1, LIMK2, CDC2, BTK).
- Western Blot analysis was performed by lysing the puromycin-selected cells in E1A buffer (50 mM Hepes pH 8; 500 mM NaCl; 0.1% NP 40; DTT 1M; EDTA 1 mM). 8-12% SDS-polyacrylamide gel electrophoresis was used to separate 30 ⁇ g of protein, which was later transferred to polyvinylidine difluoride membranes. Antibodies were then used to probe the Western Blots.
- EphA1 (2041), EphA2 (1969), EphA8 (2046), EphB2 (2048), CSF1R (1436), VEGFR2 (3791), PIK3C2A (5286), PIK3CG (5294), GSK3alpha (2931), GSK3beta (2932), IRAK3 (11213), CDC2 (983), CHEK1 (1111), LATS1 (9113), TRB3 (57761), JAK1 (3716), BTK (695), PIM1 (5292), LIMK2 (3985), PAK2 (5062).
- FIGS. 3 a - 3 c graphs are reported following silencing tests of the gene GSK3beta in the three tested tumour cell lines, in which the fraction of dead cells after the treatment with 5FU in samples infected with vectors capable of silencing the aforesaid gene is reported and compared with samples infected with empty vectors.
- FIG. 3 a compares the percentages of cell deaths in the absence (symbol “ ⁇ ”) and presence (symbol “+”) of 200 ⁇ M 5FU (72 hr treatment) upon wt HCT116 cells, HCT116p53KO drug resistant cells, and GSK3beta silenced gene cells.
- FIG. 3 b compares the percentages of cell deaths in the absence (symbol “ ⁇ ”) and presence (symbol “+”) of 200 ⁇ M 5FU (72 hr treatment) upon wt DLD-1 cells and GSK3beta silenced gene DLD-1 cells.
- GSK3beta silenced gene DLD-1 cells resulted in a high percentage of tumour cell death in the presence of 5FU.
- 3 c compares the percentages of cell deaths in the absence (symbol “ ⁇ ”) and presence (symbol “+”) of 200 ⁇ M 5FU (72 hr treatment) upon wt SW480 cells and GSK3beta silenced gene SW480 cells.
- GSK3beta silenced gene SW480 cells resulted in a high percentage of tumour cell death in the presence of 5FU.
- chemotherapeutic drugs of the antimetabolic type In addition to 5FU, representative example of the family of chemotherapeutic drugs of the antimetabolic type, the reversion of the resistance to drugs was also tested on chemotherapeutic drugs of different types, such as oxaliplatin.
- FIG. 4 a the fractions of dead cells induced by a treatment with oxaliplatin (50 ⁇ M) are reported in samples of colon tumour cell lines DLD-1 and SW480, respectively infected with empty vectors and with vectors silencing the gene GSK3beta.
- FIG. 4 b a graph is reported in which the results of an analogous test are indicated on the cell line SW480, in which the drug used was a combination of 5FU and oxaliplatin.
- GSK3alpha silencing has the same effect as GSK3beta in modulating the apoptotic response to 5FU and oxaliplatin.
- Another particularly representative example of the above-identified gene group is constituted by the gene BTK, on which several investigations were undertaken.
- BTK kinase is a cytoplasmic protein tyrosine kinase crucial for B-cell development and differentiation.
- BTK mutation is infact responsible for X-linked agammaglobulinemia (XLA), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of immunoglobulins.
- XLA X-linked agammaglobulinemia
- BTK has been reported as having either pro-apoptotic or anti-apoptotic functions.
- BTK has been so far assumed as being expressed only in some bone marrow-derived lineages such as B and mast cells, erythroid progenitors, platelets.
- FIG. 8 the results of the comparison test are reported in a graph of the functional blocking of the BTK gene by means of plasmids, siRNA or LFM-A13 in samples of HCT116p53KO cells treated with 5FU. It can be easily noted how the obtained level of reversion to the drug resistance, expressed by means of the percentage fraction of dead cells, is entirely comparable. In detail, FIG.
- FIG. 9 compares the percentages of cell deaths in the presence of 200 ⁇ M 5FU (72 hr treatment) upon wt HCT116 cells infected with empty pBabe vector, wt HCT116 cells infected with pBabe BTK vector and HCT116p53KO drug resistant cells.
- FIG. 12 a compares the percentages of cell deaths in the absence (symbol “NT” and “ ⁇ ”) and presence of 200 ⁇ M 5FU, 50 ⁇ M OxPt, and the combination of the two upon resistant ovarian (SKOV) cells with or without BTK inhibition through the usage of LMFA13.
- the SKOV cells with LMFA13 resulted in a high percentage of tumour cell death.
- FIG. 12 b compares the percentages of cell deaths in the absence (symbol “NT” and “ ⁇ ”) and presence of 200 ⁇ M 5FU, 50 ⁇ M OxPt, and the combination of the two upon resistant lung (A549) cells with or without BTK inhibition through the usage of LMFA13.
- the A549 cells without LMFA13 the A549 cells with LMFA13 resulted in a high percentage of tumour cell death.
- the high effectiveness of the action of diminution of the drug-resistance also in these cell lines confirms that the validity of the results obtained in the preceding tests can be extended at least to all types of epithelial tumour, such as lung tumour, ovarian tumour and breast tumour.
- the expression of the protein BTK is very high, at least 4-5 times greater than the expression detected on the colon carcinoma cell lines used in the functional experiments, suggesting that the determination of the BTK levels can advantageously be used as a method for defining the stem cell properties of the tumour cells examined, and consequently also their resistance to chemotherapeutic drugs.
- the predicted and reported molecular weight of BTK protein is 77 kDa.
- a bioinformatic analysis of BTK coding sequence has been carried out and, accordingly, a second nucleotide triplet ATG (nt 428-430), in frame with the one known to be used to translate traslatc BTK (nt 164-166) and susceptible to start the translation of a protein has been identified.
- the expected molecular weight of the putative protein translated starting from this second ATG is 67 kDa, consistent with the apparent molecular weight of the band identified by different BTK antibodies in epithelial carcinoma cells.
- BLAST analysis using a genomic database localize the first exon of NM — 000061 BTK transcript at 101160K on the chromosome X contig, in correspondence with the beginning of BTK locus.
- the first exon of the novel BTK transcript alignes 15192 by 5′ of the first known BTK exon, immediately downstream of the RPL36A locus, suggesting that it corresponds to a hitherto unrecognized BTK exon.
- this novel exon is present in HCT116p53KO instead of the first “classical” exon suggesting that this is an “alternative” first exon, whose usage gives raise to a different BTK mRNA, transcribed in cells expressing this shorter BTK isoform.
- the first exon of BTK corresponds to the 5′UTR of the mRNA, being the ATG triplet encoding the first Met amino acid of BTK protein located in the second exon.
- 5′UTRs usually perform regulatory functions such as directing cap-dependent or IRES-mediated cap-independent translation.
- a different first exon, as identified in the novel transcript can therefore dictate whether a different ATG (in this case an ATG located in the 4th exon) has to be used to start the translation of BTK protein, and therefore regulate the expression of different isoforms.
- nucleotide sequence of the first exon corresponding to the 5′UTR of the novel mRNA expressed by the BTK gene is reported in SEQ ID NO:1, attached to the present description.
- the amino acid sequence of the novel isoform of BTK protein coded by the novel transcript is reported in SEQ ID NO:2, attached to the present description.
- the presence of the novel isoform of the BTK protein may be controlled verifying the presence of the protein, for instance using western blot or immunoprecipitation or immunochemistry or immunofluorescence analysis, or, preferably, verifying the presence of the mRNA having the alternative first exon, whose cDNA shows the nucleotide sequence defined in SEQ ID NO:1.
- the latter may be advantageously carried out by means of PCR analysis, preferably using primers having a sequence included in SEQ ID NO:1.
- This new method is expected to show relevant advantages, whit respect to the known prior art, particularly when used for analysing tumoral tissues taken from human patients.
- tumoral tissues taken from human patients may contain an effective amount of lymphocytes which may also express BTK protein, thus disturbing the search of BTK protein expressed by the tumoral cells.
- BTK protein expressed by lymphocytes is the “classical” isoform of BTK protein having a molecular weight of 77 KDa, so that the search of the novel isoform of BTK protein may be carried out without any interference, with a simple PCR analysis looking for the presence of BTK mRNA having the alternative first exon.
- the present invention therefore resolves the above-lamented problem with reference to the mentioned prior art, offering at the same time numerous other advantages, including making possible the development of diagnostic methods capable of predicting the therapeutic response so to refine not only the diagnostics but above all direct the best therapeutic choice.
Abstract
The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.
Description
- This application is a division of U.S. Ser. No. 12/531,061, filed Sep. 25, 2009, which is a national stage filing under 35 U.S.C. 371 of International Application PCT/EP2008/053099, filed on Mar. 14, 2008, which claims priority from Italian Application No. PD2007A000088, filed on Mar. 14, 2007, and EP Application No. 07106119.6, filed on Apr. 13, 2007. The entire content of each of the referenced Application is incorporated herein by reference. International Application PCT/EP2008/053099 was published under PCT Article 21(2) in English.
- The present invention regards the use of compounds for the production of a medicament capable of modulating, and in particular diminishing the drug resistance in human epithelial tumour cells, according to the characteristics stated in the preamble of the main claim. It is also intended for a determination method of the drug resistance in tumour cells as well as a method for the identification of tumour stem cells.
- One of the most commonly followed strategies in the therapy of neoplastic pathologies foresees the use of drugs (chemotherapy) capable of damaging the DNA of the tumour cells, so as to induce the natural process of apoptosis in the same.
- Nevertheless, it is known that the tumour cells may respond in an unexpected manner to the drug therapy, showing, on the contrary, a strong resistance to the same. It is also known that one of the main reasons for the drug resistance shown by the tumour cells is the incapacity of the cells to begin the process of apoptosis, even in the presence of considerable DNA damage.
- This phenomenon was traced back to a functional alteration (mutation or deletion) of the gene p53, which is no longer capable of initiating the process of cellular apoptosis, thus leading the cells to resist the drug action. The drug resistance levels of the tumour cells can be very high. For example, in the case of tumour cells of the colon-rectum in advanced phase, a drug therapy based on 5-fluorouracil (5FU) shows an effective response only for 10-15% of the cells, and a combination of 5FU with new drugs such as irinotecan and oxaliplatin leads to an increase of the cell mortality up to 40-50%, a value which is still entirely unsatisfactory for an effective therapeutic action towards the neoplastic pathologies.
- In recent years, a cell phenomenon was discovered called “RNA interference” (RNAi) by means of which the gene expression is silenced in a specific manner. By taking advantage of such process, it is possible to obtain the selective silencing of genes with unknown function, thus permitting the definition of its specific function through the study of the obtained phenotype. By applying RNAi techniques and studying the phenotypic results, it is moreover possible to assign new functions to already known genes.
- The genes involved in the phenomenon of drug resistance of the tumour cells are today largely unknown.
- There is very much the need, therefore, to identify new genes involved in the drug-resistance and to design methods and compounds capable of substantially diminishing the tumour cells' resistance to drugs.
- The problem underlying the present invention is that of making available compounds capable of reducing the drug resistance of the tumour cells of epithelial type, in order to permit the manufacture of medicaments destined for the therapy of related neoplastic pathologies.
- This problem is resolved by the present finding by means of the use of compounds capable of functionally blocking one or more genes chosen from the group identified in the attached claims.
- In a second aspect thereof, this invention moreover provides a method for the determination of the drug resistance of epithelial tumour cell lines.
- In a further aspect thereof, this invention moreover provides a method for the identification of tumour stem cells.
- The characteristics and advantages of the invention will be clearer from the detailed description which follows of the tests and results which have led to its definition, reported with reference to the drawing set wherein:
-
FIG. 1 is a graph illustrating the results of inhibition of the capacity to form drug-resistant tumour cell colonies of the colon treated with the compounds according to the invention and a chemotherapeutic drug, -
FIGS. 2 a and 2 b are graphs showing the results of an analysis of reversion of the resistance of a tumour cell line to two different chemotherapeutic drugs by means of silencing of the alpha and beta isoforms of the gene GSK3, -
FIGS. 3 a-3 c are graphs illustrating the results of the tests of reversion of the resistance to a chemotherapeutic drug of three different tumour cell lines of the colon by means of silencing of the gene GSK3beta, -
FIG. 4 a is a graph illustrating the results of the tests of reversion of the resistance to a different chemotherapeutic drug of two different tumour cell lines of the colon by means of silencing of the gene GSK3beta, -
FIG. 4 b is a graph illustrating the results of an analysis of reversion of the resistance of a tumour cell line to the combination of two different chemotherapeutic drugs by means of the silencing of the beta isoform of the gene GSK3, -
FIG. 5 is a collection of images illustrating the location of cytochrome C for 5FU-induced cell death in the absence of GSK3. -
FIG. 6 is a graph illustrating the results ofcaspase 3 andcaspase 7 activation assays in response to 5FU treatment of HCT116 and GSK3alpha, GSK3beta gene silenced HCT116p53KO colon carcinoma cells, -
FIG. 7 is a collection of images illustrating the translocation of AIF to the nucleus during 5FU-induced cell death in the absence of GSK3, -
FIG. 8 is a graph illustrating the reversion of the resistance to a chemotherapeutic drug of a tumour cell line carried out by means of functional blocking of the gene BTK obtained with different methods, -
FIG. 9 is a graph illustrating the percentage of cell death induced by 5FU upon BTK overexpression in HCT116 colon carcinoma cells, -
FIGS. 10 a and 10 b are graphs illustrating the reversion of the resistance to chemotherapeutic drugs by means of the functional blocking of the gene BTK on different colon tumour cell lines, -
FIG. 11 is a western blot analysis showing BTK expression in several tumoral cell lines derived from different epithelial cancers, -
FIGS. 12 a and 12 b are graphs illustrating the reversion of the resistance to chemotherapeutic drugs by means of the functional blocking of the gene BTK on epithelial tumour cell lines other than colon, -
FIG. 13 is collection of images illustrating the cytoplasmic accumulation of cytochrome C in 5FU-treated cells upon BTK inhibition, -
FIG. 14 is a graph illustrating the results of fluorimetric caspase activation assays after 72 hrs and 96 hrs in HCT116 and HCT116p53KO colon carcinoma cells treated with 5FU, BTK inhibition, or the combination of the two, -
FIG. 15 a is western blot image showing that antibody sc-1696 specifically recognizes BTK protein and that in epithelial carcinoma cells (HCT116p53KO) BTK has an apparent molecular weight of ˜67 kDa and that the same form of the protein is present, together with the “classic” 77 kDa form, also in leukemic cells (Nalm6), -
FIG. 15 b is an immunoprecipitation-western blot image confirming that also a different antibody (BL7) identify BTK protein as being ˜67 kDa in HCT116p53KO cells and that this isoform is present in leukemic cells (Nalm6) together with the “classic” 77 kDa form, -
FIG. 16 is an image illustrating the results of a PCR experiment showing that the 5′ end upstream of nucleotide 202 in the BTK-encoding mRNA from HCT116p53KO cells is absent or different from the 5′ end of BTK mRNA from peripheral blood mononuclear cells (PBMC), -
FIG. 17 is an image illustrating the results of ClustalW alignment of BTK transcript, identified by GenBankAccession #NM —000061, and the novel transcript identified in HCT116p53KO cells by 5′RACE PCR followed by cloning and sequencing (indicated as alternative), the box outlining the part of BTK sequence (starting from nucleotide 131 of the known transcript) common between BTK mRNA deriving from#NM —000061 and the novel BTK transcript found in HCT116p53KO, -
FIG. 18 is an image illustrating the results of a Blast alignment vs a genomic database of exons 1-5 of BTK transcript identified by GenBank Accession# NM —000061 and the same exons of the novel BTK transcript, the dots indicating the position on chromosome X of the different exons of BTK, -
FIG. 19 is an image illustrating the results of a nested PCR experiment showing that the novel BTK transcript is expressed in Formalin-Fixed Paraffin-Embedded (FFPE) tumoral tissues from coloncarcinoma patients. - The abovementioned technical problem was tackled by subjecting several epithelial tumour cell lines to a series of tests and analyses geared to identify and characterise the genes capable of giving rise to the phenotypic expression of interest, i.e. the reversion of the resistance to the apoptosis induced by chemotherapeutic drugs.
- Such identification was conducted by means of phenotypic screening of a representative cell line of the epithelial tumour cells following the selective silencing of an extended group of genes by means of RNAi.
- This complex screening work was made possible due to a library of retroviral pRetroSuper (pRS) vectors recently made by the Bernards laboratories. It is known that such vectors are capable of expressing a specific oligonucleotide molecule in a stable manner, known as small interference RNA, in brief siRNA, capable of blocking the translation process of a specific messenger RNA (mRNA) in the corresponding protein. Such mechanism, in brief, foresees that the siRNA molecule (or rather a filament thereof) is associated with the RISC enzymatic complex, activating it, such that the latter can recognise and bind to the mRNA complementary to the siRNA associated thereto and then degrade it. It follows that the mRNA, identified in a specific manner by the siRNA, cannot be translated in the corresponding amino acid chain, thus obtaining the silencing of the gene from which the mRNA was transcribed. The interference process is specific, so that a siRNA molecule is normally capable of degrading only one mRNA and therefore silencing one single gene. On the other hand, it is instead possible that the same mRNA can be degraded, via RISC, by different siRNA.
- This mechanism is one of the different possible modes for functionally blocking a gene (functional knockout). However, the consequent degradation of siRNA via RISC produces only a transient effect on protein levels, thus allowing only short term experiments whose results may be not relevant in the long term. To overcome this problem, short hairpin RNAs (shRNAs), a sequence of RNA folded in the shape of a hairpin, were used as a mechanism for functional knockout. In brief, a vector is used to introduce and incorporate shRNA into the cell chromosome. Transcription of the DNA produces shRNA which is subsequently cleaved by the cellular machinery, DICER, into siRNA. The siRNA then functions as previously mentioned. The incorporation of the shRNA vector into the cell chromosome allows for the gene silencing to be inherited by daughter cells. Thus the usage of shRNAs allows for functional knock out cells that can be used for long term experiments.
- It is also known in the literature that the efficiency of transfection for siRNAs is never 100%. Therefore, the use of transfected siRNAs does not assure that all treated cells are successfully deprived of a target protein. The absence of a selectable marker further creates a problem in working with homogeneous populations of cells. Using a selectable marker, such as a puromycin resistance gene, along with a retroviral library, allows for recovery of only the cells bearing shRNAs. Moreover, following shRNA expression selection, only genes whose silencing is compatible with normal cell survival and proliferation are selected for. The absence of these genes does not influence normal cell physiology but only the response to anticancer drugs, a very important consideration while developing anticancer therapy.
- It is nevertheless important to specify that the same effect can, in general, be reached by acting in any other step of a gene's protein coding process, such as for example the step of transcription of the gene in mRNA, or the step of mRNA transduction, or by means of inhibition of the protein resulting from the coding process.
- It is evident that the essential and critical step in the resolution of the problem is represented by the identification of the responsible gene or genes of the desired phenotype.
- The retroviral library arranged by the Bernards laboratories consists of about 25,000 different elements, capable of silencing about 8,300 genes of the human genome, with a ratio of about 3 different vectors for each gene.
- The tests were initially conducted in vitro and subsequently validated ex vivo on different epithelial tumour cell lines, characterised by the lack of or by the mutation of the gene p53 and hence provided with a marked resistance to chemotherapeutic drugs.
- In detail, a human RNAi library (NKi library) was established, consisting of 8,300 targeted genes for silencing. The targeted genes included kinases, phosphatases, oncogenes, tumor suppressors, transcription factors, genes involved in transformation, metastasis, cell cycle, differentiation, apoptosis, metabolic and anabolic processes. A protocol was followed similar to that mentioned in a prior publication (Berns et al., NATURE vol. 428, 25 March 2004). The contents of this publication are incorporated by reference into this application. The mRNA sequence for each targeted gene was selected from UniGene. The sequences were masked using RepeatMasker to remove repetitive sequences and searched with NCBI BLAST against UniVec to mask for vector contamination. Three different 19 nucleotide (19-mer) sequences for silencing each targeted gene were designed, for a total of approximately 25,000 59-mer oligonucleotides that specify short hairpin RNAs (shRNAs). The 19-mer sequences were selected using a selection criteria as mentioned in the Berns publication wherein, a) there were no stretches of four or more consecutive T or A residues (to avoid premature polymerase III transcription termination signals); b) to have 30-70% overall GC content; c) to lie within the coding sequence of the target gene; d) to begin with a G or C residue (consistent with recently established rules for strand bias); e) to begin after an AA dimer in the 5′ flanking sequence; f) to end just prior to a TT, TG or GT doublet in the 3′ flanking sequence; g) to not contain XhoI or EcoRI restriction enzyme sites to facilitate subsequent shuttling of the knockdown cassette into vector backbones; h) to share minimal sequence identity with other genes; i) to target all transcript variants represented by RefSeq mRNAs; and j) to not overlap with other 19-mers selected from the same target sequence. The 59-mer oligonucleotides were designed as to contain a 19-mer sequence, its complimentary 19-mer sequence, pol_III transcription initiation site, pol_III termination site, and HindIII/BglII cloning sites. Utilizing the HindIII/BglII cloning sites, the oligonucleotides were ligated into pRetroSuper (pRS) retroviral vectors, which included a selection cassette for puromycin resistance. The DNA from the three different vectors that targeted the same gene was pooled and virus was produced to infect target cells.
- The tumour cell line initially used was HCT116p53KO (which differs from the wild type wt HCT116 due to the lack of gene p53), related to the colon tumour, while further detailed studies of specific genes were carried out on other drug-resistant tumour cell lines of the colon, such as DLD-1 and SW480, as well as on other tumour cell lines of the lung and ovary. In particular, all cell lines, object of the analysis, were related to tumours of epithelial type.
- Preliminarily, cell lines HCT116p53KO, DLD-1 and SW480 were treated with common chemotherapeutic drugs in order to confirm their resistance to the drug-induced apoptosis.
- The chemotherapeutic drugs usable in accordance with the present invention can be of any type suitable for inducing the apoptosis process in the affected tumour cells, such as for example an antimetabolite or any DNA-damaging agent comprising the inhibitors of the topoisomerase I, inhibitors of the topoisomerase II, the platinum coordination compounds and alkylating agents.
- The aforesaid preliminary tests have shown how, after treatment for 72 hours in 200 μM 5FU, the cell mortality was less than 10%, against a wt HCR116 cell mortality of greater than 95%.
- Supplementary tests of colony forming assays (CFA), have moreover demonstrated how such drug resistance was of non-transitory type. Once the resistance to apoptosis induced by chemotherapeutic drugs was confirmed, 200×106 HCT116p53KO cells were infected with the above-identified pRetroSuper library, provided by the Bernards laboratories. Each vector of this library was advantageously equipped with a selection cassette for a puromycin resistance gene, so that it was possible to select the HCT116p53KO cells actually infected by the vectors of the library through treatment with puromycin (2 mg/l in the culture medium for two days).
- At the end of the antibiotic treatment, the still-living cells were then collected, which therefore comprised all of the cells infected by the retroviruses of the library whose silenced genes were not incompatible with the cellular survival.
- The cells thus collected were then treated with 200 μM 5FU for 72 hours, while at the same time wt HCT116 cells and uninfected HCT116p53KO cells were also subjected to the same treatment, as controls.
- At the end of the treatment, it was found that about half of the cells were floating in the culture medium, therefore dead. Such cells represented the sought-after phenotype, so that they were collected and subjected to the necessary treatment for the identification of the genes silenced by the retroviral library.
- In brief, such treatments comprised of the extraction of the DNA and the amplification by means of PCR (Polymerase Chain Reaction) of a region of 643 base pairs containing the region H1 of a specific promoter and the adjacent region coding the nucleotide sequence of interest. PCR amplification was performed using a pRS-fw primer: 5′-CCCTTGAACCTCCTCGTTCGACC-3′ and pRS-rev primer: 5′-GAGACGTGCTACTTCCATTTGTC-3′. The products obtained by the amplification were then bound in pRS retroviral vectors and the infection process of HCT115p53KO cells was completely repeated with the new vectors, so as to refine the screening. The products were digested with EcoRI/XhoI and recloned into pRS.
- The products obtained from the second amplification treatment with PCR on the DNA harvested from the dead cells after new treatment with 5FU were newly isolated and bound in retroviral vectors pRS and then used for transforming DH5alpha bacteria whose respective plasmids were sequenced for the identification of the genes which gave rise to the phenotypic expression of interest.
- Once the single genes were obtained and identified whose silencing by means of interference with RNA gave rise to the reversion of the resistance of the tumour cells tested to the 5FU, the separated and independent validation of the single genes took place.
- Firstly, the validation was carried out in vitro on HCT116p53KO tumour cell samples, each of which separately infected with one of the previously-made plasmids, so as to silence in a specific and stable manner one of the genes indicated by the preceding screening and verify its capacity to modulate the resistance to drugs. The samples were then selected with puromycin, placed in Petri dishes at 50% confluence and treated with 200 μM of 5FU for 12 hours.
- The evaluation of the reversion of the drug resistance was carried out by means of observation of the formation of colonies according to the protocol defined by the CFA and their comparison with a wt HCT116 sample and an uninfected HCT116p53KO sample.
- In
FIG. 1 , the results are reported in graph form which were obtained from this first in vitro validation. As clearly shown by the graph, a high percentage of identified genes are capable, when functionally blocked, of consistently reverting the colony forming ability of 5FU-treated HCT116p53KO cells. HCT116 and KO represent positive and negative controls. - This first validation has in particular permitted identifying a group of genes whose specific silencing has given rise to a 5FU-induced inhibition of the growth of the tumour colonies greater than 50% with respect to the HCT116p53KO sample.
- These genes, themselves known and characterised, are listed below with their official symbol together with their identification number (between parentheses) reported on the NCBI Entrez Gene data bank: EphA1 (2041), EphA2 (1969), EphA8 (2046), EphB2 (2048), CSF1R (1436), VEGFR2 (3791), RAMP2 (10266), RAMP3 (10268), CLRN1 (7401), MAPK4 (5596), PIK3C2A (5286), PIK3CG (5294), GSK3beta (2932), IRAK3 (11213), DAPK1 (1612), JAK1 (3716), CHEK1 (1111), PIM1 (5292), TRB3 (57761), BTG1 (694), LATS1 (9113), LIMK2 (3985), MYLK (4638), PAK1 (5058), PAK2 (5062), CDC2 (983), BTK (695), PNRC2 (55629), NCOA4 (8031), NR2C1 (7181), TPR (7185), RBBP8 (5932), TRPC7 (57113), FXYD1 (5348), ERN1 (2081), PRSS16 (10279), RPS3 (6188), CCL23 (6368) and SERPINE1 (5054).
- Among the above-listed genes, a first subgroup is also identifiable of genes whose silencing advantageously leads to an over 75% inhibition of the tumour cells growth.
- Such first subgroup is formed by the following genes:
- EphA1 (2041), EphA2 (1969), EphA8 (2046), EphB2 (2048), CSF1R (1436), VEGFR2 (3791), RAMP2 (10266), RAMP3 (10268), MAPK4 (5596), PIK3C2A (5286), PIK3CG (5294), GSK3beta (2932), IRAK3 (11213), DAPK1 (1612), JAK1 (3716), CHEK1 (1111), PIM1 (5292), TRB3 (57761), BTG1 (694), LATS1 (9113), LIMK2 (3985), BTK (695), PNRC2 (55629), NCOA4 (8031), NR2C1 (7181), TPR (7185), TRPC7 (57113), FXYD1 (5348), ERN1 (2081), RPS3 (6188) and SERPINE1 (5054).
- In a more advantageous manner, a second subgroup was further identified of genes whose silencing advantageously leads to an over 95% inhibition of the growth of the tumour cells.
- Such subgroup is formed by the following genes:
- EphA1 (2041), EphA2 (1969), EphA8 (2046), RAMP3 (10268), PIK3C2A (5286), GSK3beta (2932), IRAK3 (11213), DAPK1 (1612), CHEK1 (1111), PIM1 (5292), BTK (695), NCOA4 (8031), TPR (7185).
- The gene GSKalpha (2931), isoform of the gene GSK3beta, must be added to the above-listed genes; in separate tests whose results are shown by the graphs of
FIGS. 2 a and 2 b it has shown an optimal efficiency in the reversion of the resistance both to 5FU and to the oxaliplatin in HCT116p53KO cells, entirely comparable to its beta isoform. In detail,FIG. 2 a compares the percentages of cell deaths in the absence (symbol “-”) and presence (symbol “+”) of 200 μM 5FU (72 hr treatment) upon wild type (wt) HCT116 cells, HCT116p53KO drug resistant cells, GSK3alpha and GSK3beta silenced gene cells. In comparison to the HCT116p53KO drug resistant cells, HCT116p53KO cells with GSK3alpha and GSK3beta genes silenced resulted in a high percentage of tumour cell death in the presence of 5FU.FIG. 2 b compares the percentages of cell deaths in the absence (symbol “−”) and presence (symbol “+”) of 50 μM oxaliplatin (72 hr treatment) upon wt HCT116 cells, HCT116p53KO drug resistant cells, GSK3alpha and GSK3beta silenced gene cells. In comparison to the HCT116p53KO drug resistant cells, HCT116p53KO cells with GSK3alpha and GSK3beta genes silenced also resulted in a high percentage of tumour cell death in the presence of oxaliplatin. - The formal confirmation of the silencing of the specific genes by means of interference was carried out through Western Blot analysis of the levels of the protein coded by them, if the antibody was commercially available (EphA1, EphA2, CSF1R, VEGFR, GSK3, JAK1, CHEK1, LIMK2, CDC2, BTK). Western Blot analysis was performed by lysing the puromycin-selected cells in E1A buffer (50
mM Hepes pH 8; 500 mM NaCl; 0.1% NP 40; DTT 1M;EDTA 1 mM). 8-12% SDS-polyacrylamide gel electrophoresis was used to separate 30 μg of protein, which was later transferred to polyvinylidine difluoride membranes. Antibodies were then used to probe the Western Blots. - The effectiveness of the plasmids capable of silencing the genes belonging to the above-identified group was further tested on DLD-1 and SW480, other tumour cell lines of the colon known for possessing mutated p53 and for their resistance to drugs.
- The capacity to diminish the resistance to chemotherapeutic drugs was generally confirmed, even with different performances. In particular, the inhibition percentage of the growth of colonies after drug treatment over all three cell lines was optimal when the following genes were silenced:
- EphA1 (2041), EphA2 (1969), EphA8 (2046), EphB2 (2048), CSF1R (1436), VEGFR2 (3791), PIK3C2A (5286), PIK3CG (5294), GSK3alpha (2931), GSK3beta (2932), IRAK3 (11213), CDC2 (983), CHEK1 (1111), LATS1 (9113), TRB3 (57761), JAK1 (3716), BTK (695), PIM1 (5292), LIMK2 (3985), PAK2 (5062).
- As an example, in
FIGS. 3 a-3 c graphs are reported following silencing tests of the gene GSK3beta in the three tested tumour cell lines, in which the fraction of dead cells after the treatment with 5FU in samples infected with vectors capable of silencing the aforesaid gene is reported and compared with samples infected with empty vectors. In detail,FIG. 3 a compares the percentages of cell deaths in the absence (symbol “−”) and presence (symbol “+”) of 200 μM 5FU (72 hr treatment) upon wt HCT116 cells, HCT116p53KO drug resistant cells, and GSK3beta silenced gene cells. In comparison to the HCT116p53KO drug resistant cells, HCT116p53KO cells with GSK3beta gene silenced resulted in a high percentage of tumour cell death in the presence of 5FU.FIG. 3 b compares the percentages of cell deaths in the absence (symbol “−”) and presence (symbol “+”) of 200 μM 5FU (72 hr treatment) upon wt DLD-1 cells and GSK3beta silenced gene DLD-1 cells. In comparison to the wt DLD-1 cells, GSK3beta silenced gene DLD-1 cells resulted in a high percentage of tumour cell death in the presence of 5FU.FIG. 3 c compares the percentages of cell deaths in the absence (symbol “−”) and presence (symbol “+”) of 200 μM 5FU (72 hr treatment) upon wt SW480 cells and GSK3beta silenced gene SW480 cells. In comparison to the wt SW480 cells, GSK3beta silenced gene SW480 cells resulted in a high percentage of tumour cell death in the presence of 5FU. - In addition to 5FU, representative example of the family of chemotherapeutic drugs of the antimetabolic type, the reversion of the resistance to drugs was also tested on chemotherapeutic drugs of different types, such as oxaliplatin.
- In
FIG. 4 a, the fractions of dead cells induced by a treatment with oxaliplatin (50 μM) are reported in samples of colon tumour cell lines DLD-1 and SW480, respectively infected with empty vectors and with vectors silencing the gene GSK3beta. - The substantial diminution of the resistance to the apoptosis induced by oxaliplatin in the sample in which GSK3beta was silenced is evident. In
FIG. 4 b, a graph is reported in which the results of an analogous test are indicated on the cell line SW480, in which the drug used was a combination of 5FU and oxaliplatin. - As mentioned previously and shown in
FIGS. 2 a and 2 b, GSK3alpha silencing has the same effect as GSK3beta in modulating the apoptotic response to 5FU and oxaliplatin. - Further study was conducted to determine if 5FU-induced cell death in the absence of GSK3 was cytochrome C-dependent or independent. Utilizing anti-cytochrome C and DAPI staining, as shown in
FIG. 5 , it was found that 5FU-induced cell death in the absence of GSK3 is cytochrome C-independent. More specifically, utilizing anti-AIF and DAPI staining, as shown inFIG. 7 , it was discovered that in the absence of GSK3, AIF translocates to the nucleus resulting in cell death. This was further supported by the finding thatcaspases FIG. 6 . - Another particularly representative example of the above-identified gene group is constituted by the gene BTK, on which several investigations were undertaken.
- BTK kinase is a cytoplasmic protein tyrosine kinase crucial for B-cell development and differentiation. BTK mutation is infact responsible for X-linked agammaglobulinemia (XLA), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of immunoglobulins. In B cells BTK has been reported as having either pro-apoptotic or anti-apoptotic functions. Moreover, BTK has been so far assumed as being expressed only in some bone marrow-derived lineages such as B and mast cells, erythroid progenitors, platelets. Our finding that 18 BTK is a gene whose silencing reverts resistance to the cytotoxic action of 5FU demonstrated for the first time that BTK is expressed also in cell types others than cells of the hematopoietic lineage. Firstly, the effectiveness was tested of the reversion of the resistance to drugs in HCT116p53KO tumour cells treated with an inhibitor compound of the protein BTK, such to demonstrate how the functional blocking of the gene of interest can be carried out in alternative ways to the silencing by means of RNAi.
- The compound employed in these tests was (2Z)-2-cyan-N-(2,5-dibromophenyI)-3-hydroxy-2-butenamide, known as LFM-A13, whose structural formula is reported below in
Formula 1. - In
FIG. 8 , the results of the comparison test are reported in a graph of the functional blocking of the BTK gene by means of plasmids, siRNA or LFM-A13 in samples of HCT116p53KO cells treated with 5FU. It can be easily noted how the obtained level of reversion to the drug resistance, expressed by means of the percentage fraction of dead cells, is entirely comparable. In detail,FIG. 8 compares the percentages of cell deaths in the presence of 200 μM 5FU (72 hr treatment) upon wt HCT116 cells and HCT116p53KO drug 19 resistant cells with or without (symbol “empty” and “−”) specific depletions of BTK following transient siRNA transfection (symbol “BTKi”), stable retroviral-mediated RNA interference (symbol “shBTK”), and using LFMA13, an inhibitor compound of BTK. - According to the protective effect of BTK revealed by the above described inhibition experiments, BTK overexpression protects sensitive HCT116 wt from 5FU-induced cell death. In detail,
FIG. 9 compares the percentages of cell deaths in the presence of 200 μM 5FU (72 hr treatment) upon wt HCT116 cells infected with empty pBabe vector, wt HCT116 cells infected with pBabe BTK vector and HCT116p53KO drug resistant cells. - It was also determined that BTK inhibition reverts resistance also to oxaliplatin (
FIG. 10 a) and in DLD-1 (FIG. 10 b). - The diminution of the resistance to chemotherapeutic drugs following the functional blocking of the gene BTK by means of LFM-A13 was further confirmed by tests conduct in vitro on epithelial tumour cell lines different from those of the colon. In
FIG. 11 levels of BTK have been investigated, by means of Western blot, in several different epithelial carcinoma cell lines showing that the kinase is expressed in most of them. In particular, inFIGS. 12 a and 12 b, graphs were reported of the reversion tests obtained on SKOV cell lines (related to an ovarian tumour) and A549 cell lines (related to a lung tumour). - In detail,
FIG. 12 a compares the percentages of cell deaths in the absence (symbol “NT” and “−”) and presence of 200 μM 5FU, 50 μM OxPt, and the combination of the two upon resistant ovarian (SKOV) cells with or without BTK inhibition through the usage of LMFA13. In comparison to the SKOV cells without LMFA13, the SKOV cells with LMFA13 resulted in a high percentage of tumour cell death.FIG. 12 b compares the percentages of cell deaths in the absence (symbol “NT” and “−”) and presence of 200 μM 5FU, 50 μM OxPt, and the combination of the two upon resistant lung (A549) cells with or without BTK inhibition through the usage of LMFA13. In comparison to the A549 cells without LMFA13, the A549 cells with LMFA13 resulted in a high percentage of tumour cell death. - In both cases, it is noted how the treatment of the cell lines with LFM-A13, functional inhibitor of the BTK gene, leads to a considerable increase of the cellular mortality after exposure to 5FU or oxaliplatin or both drugs in combination.
- Moreover, the high effectiveness of the action of diminution of the drug-resistance also in these cell lines, confirms that the validity of the results obtained in the preceding tests can be extended at least to all types of epithelial tumour, such as lung tumour, ovarian tumour and breast tumour.
- The optimal results pointed out above have suggested validating the gene BTK also through ex-vivo analysis on epithelial human tumour samples.
- Firstly, it was verified through Western Blot that the BTK protein levels were high in 30% of the samples of ovarian tumour cells drawn from patients in advanced stage of disease and/or resistant to chemotherapeutic drugs.
- Secondly, examinations were conducted on colon tumour stem cells isolated from patients in order to verify if the investigated genes were expressed (and in what measure) also in this cell type. In fact, according to recent studies (Dean et al., 2005), these stem cells would be the responsible principals of the drug resistance.
- In all four tumour stem cell lines analysed, isolated from different patients, the expression of the protein BTK is very high, at least 4-5 times greater than the expression detected on the colon carcinoma cell lines used in the functional experiments, suggesting that the determination of the BTK levels can advantageously be used as a method for defining the stem cell properties of the tumour cells examined, and consequently also their resistance to chemotherapeutic drugs.
- The results have shown that BTK levels determine the sensitivity of tumor cells to 5FU and that BTK inhibition reverses drug-resistance. Anti-cytochrome C immunostaining in 5FU-treated cells (
FIG. 13 ) showed cytoplasmic accumulation after 5FU treatment in resistant cells only when BTK was inhibited, supporting the finding that reversal of drug-resistance upon BTK inhibition is due to activation of apoptosis. The same finding is also supported by the graph reported inFIG. 14 , evaluating the level ofcaspase 3/7 activation upon 5FU treatment in HCT116p53KO resistant cells in the presence or in the absence of BTK inhibitor LFM-A13. High levels ofcaspase 3/7 activation, measured by means of a luminometric assay as RLU/number of cells, are observed in 5FU-treated HCT116p53KO cells only when BTK is inhibited. - The predicted and reported molecular weight of BTK protein is 77 kDa. The protein identified in western blot as BTK by a specific antibody (sc-1696, from Santa Cruz Biotechnology) in HCT116p53KO and in all other epithelial carcinoma cell lines tested (6 breast cell lines, 3 ovary cell lines, 7 lung cell lines, 5 colon cell lines), in contrast, has an apparent molecular weight around 65-68 kDa (
FIG. 11 ,FIG. 15 a) suggesting that in epithelial cell 22 lines a shorter BTK isoform is expressed. - To confirm these results an immunoprecipitation analysis was carried out using two different and specific BTK antibodies (the above cited sc-1696 and BL7, kind gift of Dr. Mike Tomlinson, University of Birmingham, UK). The results in
FIG. 15 b show that only this novel isoform is expressed in epithelial cell lines whereas in a leukemic cell line (Nalm6), already known from the literature to express the classical 77 kDa form, both isoforms are present. - Therefore, a bioinformatic analysis of BTK coding sequence (cds) has been carried out and, accordingly, a second nucleotide triplet ATG (nt 428-430), in frame with the one known to be used to translate traslatc BTK (nt 164-166) and susceptible to start the translation of a protein has been identified. The expected molecular weight of the putative protein translated starting from this second ATG is 67 kDa, consistent with the apparent molecular weight of the band identified by different BTK antibodies in epithelial carcinoma cells.
- In order to identify which portion is missing in the mRNA coding for the shorter and novel isoform of the BTK protein, PCR experiments using different primers pairs (annealing at different parts of the cds as indicated in the upper diagram of
FIG. 16 ) have been performed. As shown inFIG. 16 , these experiments indicate that the 5′ end, upstream of nucleotide 202, is absent or different in HCT116p53KO cells. 5′RACE/sequencing experiments have been performed on mRNA from HCT116p53KO cells in order to determine the identity of the unknown 5′ end. Subsequently, alignment analysis between the cDNA derived from mRNA from HCT116p53KO cells and the cDNA deriving from the standard BTK mRNA, identified by GenBankaccession #NM 000061, using ClustalW computer program (results shown inFIG. 17 ) demonstrated that the sequence upstream of the second exon (starting at nt 134 of the cds) is different from what reported in literature, i.e., epithelial colon carcinoma cells express a different first exon. - BLAST analysis using a genomic database (
FIG. 18 ) localize the first exon ofNM —000061 BTK transcript at 101160K on the chromosome X contig, in correspondence with the beginning of BTK locus. At variance, the first exon of the novel BTK transcript alignes 15192 by 5′ of the first known BTK exon, immediately downstream of the RPL36A locus, suggesting that it corresponds to a hitherto unrecognized BTK exon. Moreover, this novel exon is present in HCT116p53KO instead of the first “classical” exon suggesting that this is an “alternative” first exon, whose usage gives raise to a different BTK mRNA, transcribed in cells expressing this shorter BTK isoform. - PCR/sequencing experiments demonstrated the expression of this “alternative” BTK mRNA not only in all coloncarcinoma cell lines tested (HCT116p53KO, DLD-1 and SW480) but also in 9/9 FFPE-samples from colon carcinoma patients (
FIG. 19 ). - It should be noted that the first exon of BTK, as identified by GenBank
accession # NM —000061, corresponds to the 5′UTR of the mRNA, being the ATG triplet encoding the first Met amino acid of BTK protein located in the second exon. 5′UTRs usually perform regulatory functions such as directing cap-dependent or IRES-mediated cap-independent translation. A different first exon, as identified in the novel transcript, can therefore dictate whether a different ATG (in this case an ATG located in the 4th exon) has to be used to start the translation of BTK protein, and therefore regulate the expression of different isoforms. - The nucleotide sequence of the first exon corresponding to the 5′UTR of the novel mRNA expressed by the BTK gene is reported in SEQ ID NO:1, attached to the present description.
- The amino acid sequence of the novel isoform of BTK protein coded by the novel transcript is reported in SEQ ID NO:2, attached to the present description.
- The above results suggest a method for determining the resistance of tumour cells to chemotherapeutic drugs as well as a method for the identification of the presence of tumour stem cells, wherein the expression of gene BTK comprises the steps of verifying the presence of the novel isoform of the BTK protein.
- The presence of the novel isoform of the BTK protein may be controlled verifying the presence of the protein, for instance using western blot or immunoprecipitation or immunochemistry or immunofluorescence analysis, or, preferably, verifying the presence of the mRNA having the alternative first exon, whose cDNA shows the nucleotide sequence defined in SEQ ID NO:1. The latter may be advantageously carried out by means of PCR analysis, preferably using primers having a sequence included in SEQ ID NO:1.
- This new method is expected to show relevant advantages, whit respect to the known prior art, particularly when used for analysing tumoral tissues taken from human patients.
- Actually, it is well known that tumoral tissues taken from human patients may contain an effective amount of lymphocytes which may also express BTK protein, thus disturbing the search of BTK protein expressed by the tumoral cells.
- However, BTK protein expressed by lymphocytes is the “classical” isoform of BTK protein having a molecular weight of 77 KDa, so that the search of the novel isoform of BTK protein may be carried out without any interference, with a simple PCR analysis looking for the presence of BTK mRNA having the alternative first exon.
- The present invention therefore resolves the above-lamented problem with reference to the mentioned prior art, offering at the same time numerous other advantages, including making possible the development of diagnostic methods capable of predicting the therapeutic response so to refine not only the diagnostics but above all direct the best therapeutic choice.
Claims (22)
1-49. (canceled)
50. A method for identifying the presence of tumour cells comprising the step of measuring the level of expression of mRNA and/or the isolated active protein of a GSK3 gene, wherein said gene is the GSK3alpha or the GSK3beta isoform.
51. A method for predicting the resistance of tumour cells to chemotherapeutic drugs comprising the step of measuring the level of expression of mRNA and/or of the isolated active protein of a GSK3 gene, wherein said gene is the GSK3alpha or the GSK3beta isoform.
52. A method for predicting the reversal of resistance of tumour cells to chemotherapeutic drugs comprising the steps of a) measuring the level of expression of mRNA and/or of the isolated active protein of a GSK3 gene, b) functionally and selectively blocking the gene corresponding to said protein, c) testing the percentage of tumour cell death in the presence of chemotherapeutic drug.
53. The method according to claim 52 , wherein said GSK3 gene is the GSK3alpha or the GSK3beta isoform.
54. The method according to claim 50 , wherein said tumour cells are of epithelial type.
55. The method according to claim 50 , wherein said tumour cells are stem cells.
56. A method for reversing resistance of a tumour cell or a tumour stem cell to a chemotherapeutic drug in a tumour of a subject, the method comprising
administering to the tumour of the subject a therapeutic amount of a composition comprising a small interfering RNA (siRNA) or a small hairpin RNA (shRNA),
wherein the small interfering RNA (siRNA) or the small hairpin RNA (shRNA) inhibits expression of messenger RNA (mRNA) encoding GSK3; and
wherein inhibition of the expression of the messenger RNA (mRNA) encoding GSK3 reverses resistance of the tumour cell or the tumour stem cell to the chemotherapeutic drug.
57. A pharmaceutical composition comprising a compound capable of functionally and selectively blocking the GSK3alpha and/or the GSK3beta and a pharmaceutically acceptable vehicle.
58. A pharmaceutical composition comprising a compound capable of functionally and selectively blocking an expression of GSK3 and a chemotherapeutic drug for the treatment of an epithelial tumour.
59. The pharmaceutical composition according to claim 57 , wherein said GSK3 is a GSK3alpha or a GSK3beta.
60. The pharmaceutical composition according to claim 57 , wherein said compound capable of functionally blocking said GSK3 gene is an oligonucleotide molecule of small interference RNA (siRNA).
61. The pharmaceutical composition according to claim 57 , wherein said compound capable of functionally blocking said GSK3 is a compound capable of expressing an oligonucleotide molecule of small interference RNA (siRNA).
62. The pharmaceutical composition according to claim 57 , wherein said compound capable of functionally blocking said GSK3 gene is LiCl, tideglusib.
63. The method according to claim 58 , wherein the chemotherapeutic drug is an anti-metabolite agent.
64. The method according to claim 58 , wherein the chemotherapeutic drug is a DNA-damaging agent.
65. The method according to claim 64 , wherein the DNA-damaging agent is selected from the group consisting of a topoisomerase I inhibitor, a topoisomerase II inhibitor, a platinum coordination compound, an alkylating agent, and a combination thereof.
66. The method according to claim 58 , wherein the chemotherapeutic drug is 5-fluorouracil.
67. The method according to claim 58 , wherein the chemotherapeutic drug is oxaliplatin alone or in admixture with 5-fluorouracil (5FU).
68. A diagnostic kit for identifying the presence of tumour cells in human tissues comprising means for measuring the level of expression of a mRNA and/or the protein and/or different functional products (products phosphorylated in specific Serine or Tyrosine residues) of a GSK3 gene.
69. A diagnostic kit for predicting the resistance of tumour cells to chemotherapeutic drugs comprising means for measuring the level of expression of mRNA and/or the protein and/or different functional products (products phosphorylated in specific Serine or Tyrosine residues) of a GSK3 gene, in the presence of substances able to functionally and selectively block said gene and of a chemiotherapeutic drug.
70. The diagnostic kit according to claim 69 , wherein said gene is the GSK3alpha or the GSK3beta isoform.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/532,677 US20130041013A1 (en) | 2007-03-14 | 2012-06-25 | Isoform of bruton's tyrosine kinase (btk) protein |
US14/586,051 US9820987B2 (en) | 2007-03-14 | 2014-12-30 | Modulator compounds of drug resistance in epithelial tumor cells |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITPD2007A000088 | 2007-03-14 | ||
ITPD20070088 ITPD20070088A1 (en) | 2007-03-14 | 2007-03-14 | MODULATORY COMPOUNDS OF PHARMACOLOGICAL RESISTANCE IN TUMORAL EPITHELIAL CELLS |
EP07106119 | 2007-04-13 | ||
EPEP07106119.6 | 2007-04-13 | ||
PCT/EP2008/053099 WO2008110624A2 (en) | 2007-03-14 | 2008-03-14 | Sirna-mediated silencing of genes for treating chemotherapeutic drug-resistant epithelial tumors |
US53106109A | 2009-09-25 | 2009-09-25 | |
US13/532,677 US20130041013A1 (en) | 2007-03-14 | 2012-06-25 | Isoform of bruton's tyrosine kinase (btk) protein |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/053099 Division WO2008110624A2 (en) | 2007-03-14 | 2008-03-14 | Sirna-mediated silencing of genes for treating chemotherapeutic drug-resistant epithelial tumors |
US53106109A Division | 2007-03-14 | 2009-09-25 | |
US53206110A Division | 2007-03-14 | 2010-06-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US53206110A Continuation-In-Part | 2007-03-14 | 2010-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130041013A1 true US20130041013A1 (en) | 2013-02-14 |
Family
ID=39541876
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/531,061 Expired - Fee Related US8232085B2 (en) | 2007-03-14 | 2008-03-14 | Isoform of bruton's tyrosine kinase (BTK) protein |
US13/532,680 Expired - Fee Related US8889643B2 (en) | 2007-03-14 | 2012-06-25 | Isoform of bruton's tyrosine kinase (BTK) protein |
US13/532,677 Abandoned US20130041013A1 (en) | 2007-03-14 | 2012-06-25 | Isoform of bruton's tyrosine kinase (btk) protein |
US13/532,669 Abandoned US20130041012A1 (en) | 2007-03-14 | 2012-06-25 | New isoform of bruton's tyrosine kinase (btk) protein |
US14/514,147 Abandoned US20150150899A1 (en) | 2007-03-14 | 2014-10-14 | Isoform of Bruton's Tyrosine Kinase (BTK) Protein |
US14/586,051 Expired - Fee Related US9820987B2 (en) | 2007-03-14 | 2014-12-30 | Modulator compounds of drug resistance in epithelial tumor cells |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/531,061 Expired - Fee Related US8232085B2 (en) | 2007-03-14 | 2008-03-14 | Isoform of bruton's tyrosine kinase (BTK) protein |
US13/532,680 Expired - Fee Related US8889643B2 (en) | 2007-03-14 | 2012-06-25 | Isoform of bruton's tyrosine kinase (BTK) protein |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/532,669 Abandoned US20130041012A1 (en) | 2007-03-14 | 2012-06-25 | New isoform of bruton's tyrosine kinase (btk) protein |
US14/514,147 Abandoned US20150150899A1 (en) | 2007-03-14 | 2014-10-14 | Isoform of Bruton's Tyrosine Kinase (BTK) Protein |
US14/586,051 Expired - Fee Related US9820987B2 (en) | 2007-03-14 | 2014-12-30 | Modulator compounds of drug resistance in epithelial tumor cells |
Country Status (14)
Country | Link |
---|---|
US (6) | US8232085B2 (en) |
EP (3) | EP2550976A3 (en) |
JP (1) | JP5832721B2 (en) |
KR (1) | KR101791981B1 (en) |
CA (1) | CA2680589A1 (en) |
CY (1) | CY1115141T1 (en) |
DK (1) | DK2134374T3 (en) |
ES (1) | ES2447868T3 (en) |
HR (1) | HRP20140160T1 (en) |
PL (1) | PL2134374T3 (en) |
PT (1) | PT2134374E (en) |
RS (1) | RS53165B (en) |
SI (1) | SI2134374T1 (en) |
WO (1) | WO2008110624A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105073115A (en) * | 2013-03-14 | 2015-11-18 | 药品循环有限责任公司 | Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors |
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2680589A1 (en) * | 2007-03-14 | 2008-09-18 | Universita' Degli Studi Di Milano - Bicocca | Modulator compounds of the drug resistance in epithelial tumour cells |
AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
US9095592B2 (en) * | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US20100261776A1 (en) * | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US8178307B2 (en) * | 2009-09-02 | 2012-05-15 | National Tsing Hua University | Methods and compositions for detection of lethal cell and uses thereof |
US20120040361A1 (en) * | 2010-07-22 | 2012-02-16 | National Tsing Hua University | Methods and compositions for detection of lethal system and uses thereof |
CA2841111A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
KR20140048968A (en) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | Inhibitors of bruton's tyrosine kinase |
KR101480523B1 (en) * | 2013-02-07 | 2015-01-08 | 고려대학교 산학협력단 | siRNA for Inhibiting Endogenous rpS3 Expression |
KR101652010B1 (en) * | 2013-03-27 | 2016-08-29 | 재단법인 아산사회복지재단 | Composition comprising expression or activity inhibitor of p34 for treating or suppressing metastasis of cancer |
MX369503B (en) * | 2013-04-08 | 2019-11-11 | Pharmacyclics Llc | Ibrutinib combination therapy. |
BR112015026513A2 (en) | 2013-04-17 | 2017-07-25 | Pfizer | n-piperidin-3-ylbenzamide derivatives to treat cardiovascular disease |
EP2832358A1 (en) * | 2013-08-02 | 2015-02-04 | Bionsil S.r.l. | Pharmaceutical kit for use in the treatment of colon and colorectal cancer |
WO2015023703A1 (en) * | 2013-08-12 | 2015-02-19 | Pharmacyclics, Inc. | Methods for the treatment of her2 amplified cancer |
US20160206646A1 (en) * | 2013-08-20 | 2016-07-21 | The Research Foundation For The State University Of New York | Bruton's Tyrosine Kinase as Anti-Cancer Drug Target |
TWI617309B (en) * | 2013-10-25 | 2018-03-11 | 製藥公司 | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
US9884869B2 (en) | 2014-03-27 | 2018-02-06 | Perrigo Api Ltd. | Ibrutinib solid forms and production process therefor |
WO2015149056A1 (en) * | 2014-03-28 | 2015-10-01 | Board Of Regents, The University Of Texas System | Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury |
WO2015193702A1 (en) | 2014-06-17 | 2015-12-23 | Bionsil S.R.L. In Liquidazione | Methods for determining the sensitivity or resistance of cancer cells to at least one anticancer drug and/or therapeutically active molecule |
US9617545B2 (en) | 2014-08-28 | 2017-04-11 | Kyungpook National University Industry—Academic Cooperation Foundation | Method for treating breast cancer by targeting breast cancer stem cell |
CN104258377B (en) * | 2014-09-10 | 2017-06-30 | 中南大学湘雅医院 | Application of the PIK3C2A albumen in liver-cancer medicine is treated |
PL230756B1 (en) * | 2015-09-11 | 2018-12-31 | Univ Medyczny W Bialymstoku | Pharmaceutical set and application of erythropoietin and of the Bruton kinase inhibitor |
KR101940061B1 (en) * | 2017-06-02 | 2019-01-21 | 김준 | Composition for Inhibition of Metastasis in Cancer Cells Including Ribosomal Protein S3 siRNAs |
CN109305944B (en) * | 2017-07-28 | 2022-09-02 | 深圳睿熙生物科技有限公司 | Inhibitors of bruton's tyrosine kinase |
KR102642320B1 (en) * | 2021-02-18 | 2024-03-04 | 주식회사 베르티스 | A Composition for diagnosis of resistance to anticancer drug |
CN114399124B (en) * | 2022-03-24 | 2022-06-17 | 腾讯科技(深圳)有限公司 | Path data processing method, path planning method, path data processing device, path planning device and computer equipment |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3166008A (en) | 1962-07-26 | 1965-01-19 | Anton N Lewandoski | Apparatus for impressing type face |
US4116594A (en) | 1975-12-12 | 1978-09-26 | Magna-Graphics Corporation | Embossing apparatus having magnetic roller and flexible embossing plates therefor |
AUPN012594A0 (en) | 1994-12-16 | 1995-01-19 | Powerbeam Pty Ltd | Strengthening of poles |
US5856094A (en) * | 1995-05-12 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Method of detection of neoplastic cells |
US5989885A (en) * | 1997-01-10 | 1999-11-23 | Myriad Genetics, Inc. | Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer |
DE69918089T2 (en) * | 1998-04-17 | 2005-07-14 | Parker Hughes Institute, St. Paul | BTK INHIBITORS AND METHODS OF IDENTIFICATION AND USE |
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
JP4476491B2 (en) * | 1998-11-12 | 2010-06-09 | 栄研化学株式会社 | Gene encoding a novel transmembrane protein |
WO2001051085A1 (en) * | 2000-01-14 | 2001-07-19 | Tanox, Inc. | Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease |
DE10008215B4 (en) | 2000-02-23 | 2013-03-28 | Manroland Web Systems Gmbh | Printing unit for a rotary printing press with cross slide |
JP2004533209A (en) | 2000-10-23 | 2004-11-04 | ブリストル−マイヤーズ スクイブ カンパニー | Modulators of Bruton's tyrosine kinase and Bruton's tyrosine kinase vehicle and methods for their identification and their use in the treatment and prevention of osteoporosis and related disease states |
EP1212941A3 (en) * | 2000-11-30 | 2002-08-14 | Pfizer Products Inc. | Modulating ramp activity |
DE10141035A1 (en) | 2001-08-22 | 2003-03-20 | Nexpress Solutions Llc | Method and printing machine for determining register errors |
EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
DK2336317T3 (en) * | 2003-06-13 | 2019-12-16 | Alnylam Europe Ag | Double-stranded ribonucleic acid with increased efficiency in an organism |
DE10333626A1 (en) | 2003-07-24 | 2005-02-17 | Robert Bürkle GmbH | Device for printing on flat workpieces |
US8021831B2 (en) * | 2003-08-25 | 2011-09-20 | Board Of Regents, The University Of Texas System | Taxane chemosensitivity prediction test |
EP1791831A4 (en) * | 2003-11-19 | 2009-07-08 | Signal Pharm Llc | Methods of treating diseases and disorders by targeting multiple kinases |
JP2007512027A (en) * | 2003-11-21 | 2007-05-17 | レビビコア, インコーポレイテッド | Use of interfering RNA in the production of transgenic animals |
WO2005056766A2 (en) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
WO2005080569A1 (en) * | 2004-02-23 | 2005-09-01 | Ramot At Tel Aviv University Ltd. | Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders |
CA2563074C (en) * | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
JP5033624B2 (en) * | 2004-07-09 | 2012-09-26 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | GSK-3β alteration and proliferative disease treatment method |
EP1848418A4 (en) | 2004-10-06 | 2010-09-08 | Univ Johns Hopkins | Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection |
JP2008518207A (en) * | 2004-10-21 | 2008-05-29 | ザ ペン ステート リサーチ ファウンデーション | EPH receptor tumor biomarker |
EP1662259A1 (en) | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
US20060121511A1 (en) * | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
CN102605066A (en) * | 2004-12-08 | 2012-07-25 | 安万特药物公司 | Method for measuring resistance or sensitivity to docetaxel |
WO2006063164A2 (en) | 2004-12-08 | 2006-06-15 | Wisconsin Alumni Research Foundation | Compositions and methods for treating neuroendocrine tumors |
DE602006017964D1 (en) * | 2005-01-27 | 2010-12-16 | Burnham Inst La Jolla | EPHB RECEPTOR BINDING PEPTIDES |
EP1874793A4 (en) | 2005-04-15 | 2008-12-24 | Univ Texas | Delivery of sirna by neutral lipid compositions |
EP1915181A4 (en) * | 2005-08-10 | 2009-07-15 | Merck & Co Inc | Novel hiv targets |
DE202005017869U1 (en) | 2005-11-16 | 2006-07-13 | Rosas Wolf, David | Single copy feeder and transport system for producing a folded printed box for the pharmaceutical industry comprises a feeder disposed with a register control unit via a servo drive |
US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
US8389207B2 (en) * | 2006-06-08 | 2013-03-05 | Salk Institute For Biological Studies | Methods for identifying candidate fat-mobilizing agents |
CA2680589A1 (en) * | 2007-03-14 | 2008-09-18 | Universita' Degli Studi Di Milano - Bicocca | Modulator compounds of the drug resistance in epithelial tumour cells |
-
2008
- 2008-03-14 CA CA 2680589 patent/CA2680589A1/en not_active Abandoned
- 2008-03-14 DK DK08717840T patent/DK2134374T3/en active
- 2008-03-14 EP EP20120179801 patent/EP2550976A3/en not_active Withdrawn
- 2008-03-14 SI SI200831158T patent/SI2134374T1/en unknown
- 2008-03-14 EP EP20120179806 patent/EP2546651A1/en not_active Withdrawn
- 2008-03-14 KR KR1020097021313A patent/KR101791981B1/en active IP Right Grant
- 2008-03-14 PL PL08717840T patent/PL2134374T3/en unknown
- 2008-03-14 JP JP2009553158A patent/JP5832721B2/en not_active Expired - Fee Related
- 2008-03-14 WO PCT/EP2008/053099 patent/WO2008110624A2/en active Application Filing
- 2008-03-14 RS RSP20140079 patent/RS53165B/en unknown
- 2008-03-14 US US12/531,061 patent/US8232085B2/en not_active Expired - Fee Related
- 2008-03-14 ES ES08717840T patent/ES2447868T3/en active Active
- 2008-03-14 PT PT87178406T patent/PT2134374E/en unknown
- 2008-03-14 EP EP20080717840 patent/EP2134374B1/en active Active
-
2012
- 2012-06-25 US US13/532,680 patent/US8889643B2/en not_active Expired - Fee Related
- 2012-06-25 US US13/532,677 patent/US20130041013A1/en not_active Abandoned
- 2012-06-25 US US13/532,669 patent/US20130041012A1/en not_active Abandoned
-
2014
- 2014-02-19 HR HRP20140160AT patent/HRP20140160T1/en unknown
- 2014-02-20 CY CY20141100142T patent/CY1115141T1/en unknown
- 2014-10-14 US US14/514,147 patent/US20150150899A1/en not_active Abandoned
- 2014-12-30 US US14/586,051 patent/US9820987B2/en not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
US10004746B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10004745B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton'S tyrosine kinase (Btk) |
US10016435B2 (en) | 2010-06-03 | 2018-07-10 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10478439B2 (en) | 2010-06-03 | 2019-11-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (Btk) |
US10653696B2 (en) | 2010-06-03 | 2020-05-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (BTK) |
US10751342B2 (en) | 2010-06-03 | 2020-08-25 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US11672803B2 (en) | 2010-06-03 | 2023-06-13 | Pharmacyclics Llc | Use of inhibitors of Brutons tyrosine kinase (Btk) |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
CN105073115A (en) * | 2013-03-14 | 2015-11-18 | 药品循环有限责任公司 | Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
Also Published As
Publication number | Publication date |
---|---|
JP5832721B2 (en) | 2015-12-16 |
WO2008110624A2 (en) | 2008-09-18 |
US8889643B2 (en) | 2014-11-18 |
EP2134374B1 (en) | 2013-11-20 |
EP2134374A2 (en) | 2009-12-23 |
US8232085B2 (en) | 2012-07-31 |
WO2008110624A3 (en) | 2008-11-27 |
DK2134374T3 (en) | 2014-02-24 |
US20100081704A1 (en) | 2010-04-01 |
EP2550976A3 (en) | 2013-04-03 |
US20150111953A1 (en) | 2015-04-23 |
EP2546651A1 (en) | 2013-01-16 |
US20150150899A1 (en) | 2015-06-04 |
HRP20140160T1 (en) | 2014-03-28 |
CY1115141T1 (en) | 2017-01-25 |
US20130041012A1 (en) | 2013-02-14 |
US9820987B2 (en) | 2017-11-21 |
KR101791981B1 (en) | 2017-11-01 |
CA2680589A1 (en) | 2008-09-18 |
RS53165B (en) | 2014-06-30 |
ES2447868T3 (en) | 2014-03-13 |
PT2134374E (en) | 2014-03-03 |
PL2134374T3 (en) | 2014-11-28 |
US20130041014A1 (en) | 2013-02-14 |
EP2550976A2 (en) | 2013-01-30 |
KR20100015529A (en) | 2010-02-12 |
JP2010521439A (en) | 2010-06-24 |
SI2134374T1 (en) | 2014-03-31 |
WO2008110624A9 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8889643B2 (en) | Isoform of bruton's tyrosine kinase (BTK) protein | |
Wu et al. | CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis | |
Zhang et al. | MiR-337–3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB | |
Yeh et al. | MicroRNA‐138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF‐1α | |
Raver-Shapira et al. | Transcriptional activation of miR-34a contributes to p53-mediated apoptosis | |
Nohata et al. | Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC) | |
Zhan et al. | MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1 | |
Chang et al. | MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3 | |
EP2753692B1 (en) | Microrna-based methods and assays for osteosarcoma | |
Wang et al. | Polypyrimidine tract-binding protein (PTB) differentially affects malignancy in a cell line-dependent manner | |
Liu et al. | FUS‐induced circular RNA ZNF609 promotes tumorigenesis and progression via sponging miR‐142‐3p in lung cancer | |
Ohno et al. | The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma | |
JP2015501645A (en) | MiRNAs and related compositions and methods useful for reducing tumor development and chemotherapy resistance in lung cancer | |
Kim et al. | Primate-specific miR-944 activates p53-dependent tumor suppression in human colorectal cancers | |
TW202018090A (en) | Expression inhibitor of cancer promoting factor, screening method of effecive ingrediaetnts thereof, expression cassette useful in the method, disgonostic agent and diagnostic method | |
Zhu et al. | SP1/AKT/FOXO3 signaling is involved in miR-362-3p-mediated inhibition of cell-cycle pathway and EMT progression in renal cell carcinoma | |
Dai et al. | MiR-501-3p promotes osteosarcoma cell proliferation, migration and invasion by targeting BCL7A | |
Lin et al. | Erratum to: Negative feedback of miR-29 family TET1 involves in hepatocellular cancer | |
CN107267616B (en) | Application of non-coding gene biomarker in liver cancer | |
CN107227362B (en) | Gene related to liver cancer and application thereof | |
Lavitrano et al. | Isoform of bruton's tyrosine kinase (BTK) protein | |
US10905708B2 (en) | MicroRNA-based methods and assays for osteocarcinoma | |
US11260072B2 (en) | MicroRNA-based methods and assays for osteocarcinoma | |
Lavitrano et al. | Isoform of bruton's tyrosine kinase (BTK) protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |